Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Stock Chart & Stats
$24.70
-$4.21(-8.86%)
At close: 4:00 PM EST
$24.70
-$4.21(-8.86%)
Day’s Range― - ―
52-Week Range$23.15 - $56.70
Previous CloseN/A
Volume7.58M
Average Volume (3M)9.72M
Market Cap
$9.65B
Enterprise Value$6.31B
Total Cash (Recent Filing)$5.13B
Total Debt (Recent Filing)$741.00M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 06, 2025EPS Estimate
-2.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding390,580,780
10 Day Avg. Volume8,274,245
30 Day Avg. Volume9,717,436
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.46
Price to Sales (P/S)4.99
P/FCF Ratio-3.94
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$41.40Price Target Upside67.61% Upside
Rating ConsensusHold
Number of Analyst Covering20
Bulls Say, Bears Say
Bulls Say
Bears Say
Financial PerformanceThe Q3 operating expenses were increased to $1.2B, resulting in a larger unadjusted GAAP EPS loss.
Sales ProjectionsThe probability of success for mRNA-1647 in congenital CMV has been lowered to 0%, significantly impacting future sales projections.
Vaccine DevelopmentThe Phase 3 pivotal study of mRNA-1647 (CMV vaccine) did not meet its primary efficacy endpoint of preventing CMV infection, leading to the discontinuation of congenital CMV development.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $23.15 and its highest was $56.70 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $9.65B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Nov 06, 2025 which is in 6 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Aug 01, 2025. The company reported -$2.13 earnings per share for the quarter, beating the consensus estimate of -$2.989 by $0.859.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.12.
How many shares outstanding does Moderna have?
Moderna has 390,580,780 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$2.13 in its last earnings report, beating expectations of -$2.989. Following the earnings report the stock price went down -6.631%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$41.40 (67.61% Upside)
$41.40 (67.61% Upside)
Blogger Sentiment
Bullish
MRNA Sentiment 73%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.26%
12-Months-Change
Fundamentals
Return on Equity
-27.50%
Trailing 12-Months
Asset Growth
-23.41%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development of messenger RNA (mRNA) therapeutics and vaccines. Founded in 2010, Moderna focuses on creating innovative medicines for infectious diseases, immuno-oncology, and rare diseases, with its most notable product being the mRNA-1273 vaccine for COVID-19. The company operates primarily in the biotechnology sector and is known for its cutting-edge technology platform that enables rapid development and manufacturing of mRNA-based solutions.
MRNA Company Deck
MRNA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant progress in vaccine approvals and cost reductions, but these were offset by declining revenues, financial losses, and a workforce reduction. While Moderna is making strides in its strategic priorities, the challenges in revenue and operational adjustments indicate uncertainty in the near term.View all MRNA earnings summariesMRNA Revenue Breakdown
55.16% U.S.
26.36% Rest of World
18.48% Europe
MRNA Stock 12 Month Forecast
Average Price Target
$41.40
▲(67.61% Upside)
Technical Analysis
Ownership Overview
7.71% Insiders
19.78% Mutual Funds
0.35% Other Institutional Investors
47.74% Public Companies and Individual Investors